Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-05 4:15 pm Sale | 13D | KINNATE BIOPHARMA INC KNTE | Foresite Capital Fund V L.P. | 0 0% | -13,779,062 (Position Closed) | View |
| 2024-02-22 4:39 pm Unchanged | 13D | KINNATE BIOPHARMA INC KNTE | Foresite Capital Fund V L.P. | 13,779,062 29.2% | 0 (Unchanged) | View |
| 2024-02-21 4:11 pm Unchanged | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.1% | 0 (Unchanged) | View |
| 2024-02-14 4:16 pm Sale | 13G | KINNATE BIOPHARMA INC KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 0 0% | -2,329,480 (Position Closed) | View |
| 2024-02-14 4:00 pm Sale | 13G | KINNATE BIOPHARMA INC KNTE | TANG CAPITAL PARTNERS LP | 2,601,647 5.5% | -364,068 (-12.28%) | View |
| 2024-02-14 09:21 am Sale | 13G | KINNATE BIOPHARMA INC KNTE | Lynx1 Capital Management LP | 1,997,006 4.2% | -216,172 (-9.77%) | View |
| 2023-11-27 4:47 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | TANG CAPITAL PARTNERS LP | 2,965,715 6.3% | 2,965,715 (New Position) | View |
| 2023-11-17 08:27 am Unchanged | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16% | 0 (Unchanged) | View |
| 2023-11-17 08:00 am Unchanged | 13D | KINNATE BIOPHARMA INC KNTE | Foresite Capital Fund V L.P. | 13,779,062 29.2% | 0 (Unchanged) | View |
| 2023-11-14 4:57 pm Unchanged | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16% | 0 (Unchanged) | View |
| 2023-11-14 4:30 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | Foresite Capital Fund V L.P. | 13,779,062 29.2% | 13,779,062 (New Position) | View |
| 2023-08-14 5:00 pm Sale | 13G | KINNATE BIOPHARMA INC KNTE | RA CAPITAL MANAGEMENT L.P. | 0 0% | -4,264,144 (Position Closed) | View |
| 2023-05-10 5:20 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | Foresite Capital Fund IV L.P. | 13,718,311 29.5% | 1,780,000 (+14.91%) | View |
| 2023-05-08 5:01 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.2% | 1,460,932 (+23.95%) | View |
| 2023-05-02 7:28 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 6,098,797 13.1% | 1,405,168 (+29.94%) | View |
| 2023-04-06 09:29 am Sale | 13G | KINNATE BIOPHARMA INC KNTE | BlackRock Inc. BLK | 2,277,109 4.9% | -58,709 (-2.51%) | View |
| 2023-02-23 3:23 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 4,693,629 10.6% | 1,295,700 (+38.13%) | View |
| 2023-02-22 3:01 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | Foresite Capital Fund IV L.P. | 11,938,311 25.6% | 1,100,000 (+10.15%) | View |
| 2023-02-14 4:45 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | RA CAPITAL MANAGEMENT L.P. | 4,264,144 9.7% | 671,092 (+18.68%) | View |
| 2023-02-14 4:32 pm Sale | 13G | KINNATE BIOPHARMA INC KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 2,329,480 5.3% | -678,763 (-22.56%) | View |